New Horizons for Cardiovascular Health

a personalised approach to preventing the preventable by using digitalisation and health data

Dr. Marius Geanta
FH Europe Foundation
Trustee and Chair of the Policy and Innovation Advisory Committee
CVDs in numbers - personal, familial, societal and economic impact

• **17.9 million** people died from CVDs in 2019 – the major cause of mortality and morbidity globally

• **85%** of death due to heart attack and stroke

• **more than 75%** deaths in LMICs

• **EUR 210 billion** per year in Europe – the cost of CVDs
CVDs prevention, early detection and screening: insufficient and/or inefficient

- **health systems design** - hospital-centric, prioritising the diagnostic and treatment
- **misconceptions** around CVDs prevention and development (“lifestyle disease”)
- **low awareness rate** at population level on methods to promote and preserve CVH
- **low interest** of relevant stakeholders in the implementation of evidence-based screening and early detection (FH screening, Lp(a) testing)
- **low awareness of non-modifiable factors such as genetic** factors in CVDs pathogenesis
- **low integration** of all cardiovascular health determinants (social, economic, demographic, environmental and behavioral factors)
Determinants of HEALTH
Model of all factors correlated with health outcomes for an individual

- Physical environment (7%)
- Health system (11%)
- Biologic, genetic factors (22%)
- Socio-Individual (36%)

Source: https://determinatsofhealth.org
Familial Hypercholesterolemia
The world’s most common and non-modifiable CVD risk factor

- Genetically determined, dangerously high level of LDL cholesterol in the blood
- 2 forms: heterozygous (common) and homozygous (very rare and very severe)
- Undetected and untreated/unmanaged, leads to early heart attacks, heart disease and even deaths, as early as 4 years of age (HoFH).

- 1 in 300 people have FH
  - 50% is the risk of inheriting FH from a parent with FH
- Every minute a child with FH is born somewhere in the world
- Every day a child with HoFH is born somewhere in the world
- 1 in 17 heart attacks is due to FH, which could have been prevented
- Less than 10% of people with FH are diagnosed and adequately treated
- Over 30 million people worldwide have FH, and 90% still do not know it!!!!
Therefore, a combination of screening methods - universal paediatric screening, (reverse) cascade screening – family screening members (parents, siblings, children) of index cases, and opportunistic screening – is essential.
Digitalization and health data
Key pillar in advocacy for CVD prevention

The Time is Now:
Achieving FH Paediatric Screening Across Europe


Technical Meeting on
Achieving Equity and Innovation in Newborn Screening and in Familial Hypercholesterolaemia Paediatric Screening across Europe.

11th October 2021

The Prague Declaration
6 September 2022
Role of patients in advocacy for implementation

Innovation through multidisciplinary collaboration
High lipoprotein (a)  
An independent CVD risk factor

• Lp(a) level is **genetically** determined

• Every person reaches the lifetime level of circulating Lp(a) already in **early childhood**

• LP(a) levels are independent of **lifestyle**

• High levels of Lp(a) affect **1 in 5 people**, this means est. **1.4 billion** people globally

• If one of the parents has elevated Lp(a), there is a greater chance of inheriting this risk factor

• **Males and females are equally** likely to have the genetic high levels of Lp(a).
Lp(a) International Initiative
Vision of the International Lp(a) Initiative

Lp(a) measurement is the norm globally, and elevated Lp(a) is managed efficiently and equitably, to contribute towards the prevention of premature cardiovascular disease and related deaths.
Members of the Lp(a) International Task Force

Magdalena Daccord
FH Europe Foundation
The Netherlands/Europe

Prof. Zanfina Ademi
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Australia

Dr Pia R. Kamstrup
Copenhagen University Hospital Denmark

Prof. Florian Kronenberg
University of Innsbruck Austria

Dr Jean-Luc Eiselé
World Heart Federation Switzerland/Global

Lena Lymeropoulou
Novartis Switzerland/Global

Dr Marius Geantă
Centre for Innovation in Medicine, FH Europe Foundation Romania

Bogi Eliasen
Copenhagen Institute for Futures Studies Denmark/Global

Marc Rijken
KLM Lp(a) Patient Ambassador The Netherlands

Nicola Bedlington
Millwater Partners GmbH, FH Europe Foundation Austria

Dr Andrija Janičijević
Roche Diagnostics Int. Switzerland/Global

Dr George Thanassoulis
McGill University Health Centre Canada
In parallel, a process will be outlined to establish national task forces in the three key countries (Canada, China and Japan) to enable implementation.

Goals

1. To raise awareness about Lp(a) as an independent and a major inherited CVD risk factor and how this can be effectively managed among policy makers, health care professionals, patients and the public.

2. To demonstrate the cost-effectiveness of CVD prevention through the diagnosis of high levels of Lp(a) as a strategy towards CVD prevention.

3. To test personalised prevention models in health systems focussing on implementation science in the field of Lp(a).

4. To utilise effectively digital transformation and health data to support research and sound decision-making in the context of Lp(a).

5. To devise a forward-looking research and policy agenda in Lp(a) anticipating trends and critical issues, in collaboration with social futurists.
Data and digitalization enabling PERSONALISED PREVENTION of CVD – digital screening

- Hospital information systems
- EHRs
- Registries

Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation

Next BIG thing: patient’s and citizen’s generated data

- Medical data
- Lifestyle data
- Behavioural data
- Socio-economic data
- Environmental data

• Virtual Twin
Determinants of HEALTH
Model of all factors correlated with health outcomes for an individual

Source: https://determinatsofhealth.org
Personalised Communication Models Concept – Citizen Matrix based
Towards a new model shift from CVD to CVH

- Human-centric, data-driven
- “Whole of society” approach
- Top-down and bottom-up
- Distributed leadership
- Incorporating innovations coming from biotech revolution (genomics, RNA-based therapies, gene editing, gene therapies etc)
“The electric light did not come from the continuous improvement of candles” – (Oren Harari)
Call to Action: A Global Code for Cardiovascular HEALTH

- co-creation process involving key stakeholders (traditional and non-traditional)
- evidence-based recommendations to promote and to preserve CVH
- frameworks for implementation in real life settings
- policy recommendations aiming to increase the uptake of the Code for CVH
THANK YOU

www.fhef.org

X.com/MGeanta
Linkedin.com/MGeanta